ClinicalTrials.gg
CompletedNCT00366145Updated Feb 10, 2022

Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)

A Phase 3 interventional study of Prochymal® and Placebo in Graft Versus Host Disease, sponsored by Mesoblast, Inc.. Completed at 70 sites in 6 countries. Open to participants aged 6 Months to 70 Years. Per ClinicalTrials.gov, last updated 2022-02-10.

Sponsored by Mesoblast, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2008, 17 years 10 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Aug 2010.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
6 Months to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 454 studies in Graft vs Host Disease with a site in United States — 50 open to participants now, 71 under way, 2 of them phase 3. Graft vs Host Disease · United States.

Enrollment
9th of 389
260 · median 30
Started
2006
with 16 others
Phase 3
40 of 454
2 open now
Registered
118th of 454
by date

Among the 454 studies in Graft vs Host Disease with a site in United States, this one is the 9th largest by enrollment of the 389 interventional ones that give a count, is one of 17 that started in 2006, is one of 40 in phase 3, and was the 118th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

50 of the 454 studies in Graft vs Host Disease with a site in United States are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 6 Months to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Graft vs Host Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and gather additional safety information for Prochymal® in participants who have failed to respond to steroid treatment of Grades B-D acute GVHD.

Read the detailed description

Approximately 6300 patients receive allogeneic hematopoietic stem cell transplants in the United States each year (International Bone Marrow Transplant Registry [IBMTR], 2003). Nearly 50% (approximately 3,150) of these patients develop acute GVHD (Goker et al). A fraction of these patients (approximately 870) will progress to the severe stages of the disease, Grades III-IV. It is estimated that nearly 82% of those patients with severe acute GVHD will be steroid refractory (Przepiorka et al., 1995) and of these, only 50% of steroid-refractory patients will respond to secondary and tertiary treatments (Greinix et al., 2000). Thus, roughly 350 patients each year face tremendous odds against survival. In addition, most patients who initially responded to secondary and tertiary treatments have a high risk of dying within the first year (Remberger et al., 2001; Anasetti et al., 1994). Development of new therapeutic agents and strategies to rescue patients with steroid refractory, acute GVHD would provide a significant benefit in an area of unmet medical need. Participants will receive standard of care in addition to adult mesenchymal stem cells or placebo.

03

Conditions studied

  • Graft Versus Host Disease

Browse trials for

Keywords

  • Acute GVHD
  • Steroid refractory GVHD
  • Severe steroid refractory acute GVHD
  • Steroid refractory
  • Steroid Refractory Acute Graft Versus Host Disease
04

Who can participate

Ages eligible
6 Months to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 6 months to 70 years of age, inclusive.
  • Participants who have failed to respond to treatment.

Failure to respond to steroid treatment is defined as any grade B-D (IBMTR) grading of acute that shows:

  • No improvement after 3 days and a duration of no greater than 2 weeks while receiving treatment with methylprednisolone (greater than or equal to 1 mg/kg/day) or equivalent.
  • Participant must be treated within 4 days of randomization. In urgent situations therapy may be started 24 hours prior to randomization, and Prochymal® must be initiated within the following 3 days.
  • Participants who have received an increase in their steroid dose treatment prior to randomization will be eligible for enrollment. An increase in steroid dose will not be considered as second line therapy.
  • Participant must have adequate renal function as defined by: Calculated of >30 milliliters per minute (mL/min) using the Cockcroft-Gault equation.
  • For pediatric participants: Schwartz equation: (Participant population: infants over 1 week old through adolescence (\<18 years old).
  • Participants who are women of must be non-pregnant, not breast-feeding, and use adequate . Male participants must use adequate contraception.
  • Participant must have a minimum Performance Level of at least 30 at the time of study entry.
  • Participant (or legal representative where appropriate) must be capable of providing written .

Exclusion criteria

Exclusion Criteria:

  • Participant has started treatment with therapy >24 hours prior to randomization.
  • Participant has received agents other than for primary treatment of acute .
  • Participant is participating in the CTN Protocol 0302.
  • Participant has any underlying or current medical or psychiatric condition that, in the opinion of the Investigator, would interfere with the evaluation of the participant including uncontrolled infection, heart failure, pulmonary hypertension, etc.
  • Participant may not receive any other agents (not approved by the FDA) concurrently during study participation or within 30 days of randomization.
  • Participant has a known allergy to bovine or porcine products.
  • Participant has received a transplant for a solid tumor disease.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
260 participants (actual)

Study arms

  • Active comparator
    Prochymal®

    Participants who receive standard of care plus treatment with ex vivo cultured adult human mesenchymal stem cells.

    Biological: Prochymal® · Drug: Standard of Care for GVHD

  • Placebo comparator
    Placebo

    Participants who receive standard of care and do not receive treatment with ex vivo cultured adult human mesenchymal stem cells.

    Drug: Placebo · Drug: Standard of Care for GVHD

Interventions

  • BiologicalProchymal®

    2 infusions of 2 million cells/kg per week for 4 weeks

    Also known as: Mesenchymal Stem Cells

  • DrugPlacebo

    2 infusions per week for 4 weeks

    Also known as: excipients without adult human mesenchymal stem cells

  • DrugStandard of Care for GVHD

    Institutionally defined standard of care (e.g., maintenance of steroid treatment and the addition of a second-line therapy)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants achieving Complete Response of Greater Than or Equal to 28 Days Duration

    A complete response was defined as complete resolution of all clinical signs of Graft versus host disease (GVHD)- that had to be maintained for at least 28 consecutive days (durable complete response \[DCR\]) within 100 days post first infusion.

    Time frame: up to 100 Days post first infusion

Secondary outcomes

  1. Overall Survival at 180 days Post First Infusion

    Percentage of participants who survived at 180 days post first infusion.

    Time frame: Day 180

07

Study locations

70 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35249, United States
  • Arizona Cancer Center
    Tucson, Arizona 85724, United States
  • City of Hope
    Duarte, California 91010, United States
  • Univeristy of California San Francisco
    San Francisco, California 94143, United States
  • Yale New Haven Hospital
    New Haven, Connecticut 06520, United States
  • University of Miami
    Miami, Florida 33136, United States
  • All Children's Hospital
    Saint Petersburg, Florida 33701, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Northside Hospital
    Atlanta, Georgia 30342, United States
  • Northwestern Center for Clinical Research
    Chicago, Illinois 60611, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Illinois - Chicago
    Chicago, Illinois 60612, United States
  • Indiana Blood and Bone Marrow Transplant Center
    Beech Grove, Indiana 46107, United States
  • Univeristy of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Louisiana State University
    Shreveport, Louisiana 71130, United States
  • University of Maryland/Greenbaum
    Baltimore, Maryland 21201, United States
  • Tufts-New England Medical Center
    Boston, Massachusetts 02111, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Karmanos/Wayne State University
    Detroit, Michigan 48201, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • Univeristy of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
  • University of Nebraska
    Omaha, Nebraska 68198, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Roswell Park
    Buffalo, New York 14263, United States
  • New York Presbyterian Hospital
    New York, New York 10021, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • Columbia University/New York Presbyterian Hospital
    New York, New York 10032, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • New York Medical College
    Valhalla, New York 10595, United States
  • Duke University
    Durham, North Carolina 27710, United States
  • Wake Forest Univeristy School of Medicine
    Winston-Salem, North Carolina 27157, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Penn State Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Western Pennsylvania Cancer Institute
    Pittsburgh, Pennsylvania 15224, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Texas Cancer Center at Medical City
    Dallas, Texas 75230, United States
  • Baylor University
    Dallas, Texas 75246, United States
  • Univeristy of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Texas Research Center
    San Antonio, Texas 78229, United States
  • Virginia Commonwealth/Massey Cancer Center
    Richmond, Virginia 23298, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109-1024, United States
  • University of Wisconsin Madison
    Madison, Wisconsin 53792, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Royal Brisbane Hospital
    Herston, Queensland 4029, Australia
  • Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • Royal Perth Hospital
    Perth, Western Australia 6100, Australia
  • Co-Medica Research Network
    Calgary, Alberta T1Y6J4, Canada
  • British Columbia's Children's Hospital
    Vancouver, British Columbia V6H3V4, Canada
  • Cancer Care Manitoba
    Winnipeg, Manitoba R3E0V9, Canada
  • Queen Elizabeth II Health Sciences Centre
    Halifax, Nova Scotia B3H2Y9, Canada
  • Hamilton Health Sciences Centre
    Hamilton, Ontario L8N3Z5, Canada
  • London Health Sciences Centre- Westminster Campus
    London, Ontario N6A4G5, Canada
  • Ottawa Hospital
    Ottawa, Ontario K1H8L6, Canada
  • Toronto General Hospital
    Toronto, Ontario M5G 1X8, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5G1X8, Canada
  • Maisonneuve-Rosemont Hospital
    Montreal, Quebec H1T 2M4, Canada
  • Hopital Enfant-Jesus
    Quebec, G1J 1Z4, Canada
  • Hopital du Saint-Sacrement
    Quebec, G1S4L8, Canada
  • Universia degli Studi di Pesaro
    Pesaro, PU 61100, Italy
  • IRCCS Policlinico San Matteo
    Pavia, 27100, Italy
  • Kantonsspital Basel
    Basel, 4031, Switzerland
  • Barts & London School of Medicine
    London, England EC1M 6BQ, United Kingdom
  • John Radcliffe Hospital
    Headington, Oxford OX3 0Du, United Kingdom
  • Bristol Royal Hospital for Children
    Bristol, UK BS2 8BJ, United Kingdom
  • Glasgow Royal Infirmary
    Glasgow, UK G4 OSF, United Kingdom
  • Leeds General Infirmary
    Leeds, UK LS1 3EX, United Kingdom
08

References and documents

Publications

  • Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002 Jan;30(1):42-8. doi: 10.1016/s0301-472x(01)00769-x. PubMed 11823036 ↗
  • Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol. 2000 Aug;28(8):875-84. doi: 10.1016/s0301-472x(00)00482-3. PubMed 10989188 ↗
  • Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, McCarthy P, Atkinson K, Cooper BW, Gerson SL, Laughlin MJ, Loberiza FR Jr, Moseley AB, Bacigalupo A. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant. 2005 May;11(5):389-98. doi: 10.1016/j.bbmt.2005.02.001. PubMed 15846293 ↗
  • Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004 May 1;363(9419):1439-41. doi: 10.1016/S0140-6736(04)16104-7. PubMed 15121408 ↗
  • Le Blanc K, Pittenger M. Mesenchymal stem cells: progress toward promise. Cytotherapy. 2005;7(1):36-45. doi: 10.1080/14653240510018118. PubMed 16040382 ↗
  • Camilleri ET, Gustafson MP, Dudakovic A, Riester SM, Garces CG, Paradise CR, Takai H, Karperien M, Cool S, Sampen HJ, Larson AN, Qu W, Smith J, Dietz AB, van Wijnen AJ. Identification and validation of multiple cell surface markers of clinical-grade adipose-derived mesenchymal stromal cells as novel release criteria for good manufacturing practice-compliant production. Stem Cell Res Ther. 2016 Aug 11;7(1):107. doi: 10.1186/s13287-016-0370-8. PubMed 27515308 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2006 to primary completion in Dec 2008, 28 months.

Of 31 phase 3 interventional studies under Graft vs Host Disease, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 48. This study's 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2006
First posted
Aug 21, 2006
StartActual
Aug 17, 2006
Primary completionActual
Dec 26, 2008
CompletionActual
May 28, 2009
Results delay requested
Aug 24, 2010
Last update
Feb 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00366145
Lead sponsor
Mesoblast, Inc.
Responsible party
Sponsor
First posted
Aug 21, 2006
Start date
Aug 17, 2006
Primary completion
Dec 26, 2008
Completion
May 28, 2009
Last update
Feb 10, 2022

Study contacts

Christopher James, PA
study director · Mesoblast, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remestemcel-l

Start the discussion